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SteroidogenesisThe role of adrenal hexose-6-phosphate dehydrogenase in providing reducing equivalents to P450 cytochrome
steroidogenic enzymes in the endoplasmic reticulum is uncertain. Hexose-6-phosphate dehydrogenase resides in
the endoplasmic reticulum lumen and co-localizeswith the bidirectional enzyme11β-hydroxysteroid dehydroge-
nase 1. Hexose-6-phosphate dehydrogenase likely provides 11β-hydroxysteroid dehydrogenase 1 with NADPH
electrons via channeling. Intracellularly, two compartmentalized reactions generate NADPH upon oxidation of
glucose-6-phosphate: cytosolic glucose-6-phosphate dehydrogenase and microsomal hexose-6-phosphate
dehydrogenase. Because some endoplasmic reticulum enzymes require an electron donor (NADPH), it is
conceivable that hexose-6-phosphate dehydrogenase serves in this capacity for these pathways. Besides
11β-hydroxysteroid dehydrogenase 1, we examined whether hexose-6-phosphate dehydrogenase generates re-
duced pyridine nucleotide for pivotal adrenal microsomal P450 enzymes. 21-hydroxylase activity was increased
with glucose-6-phosphate and, also, glucose and glucosamine-6-phosphate. The latter two substrates are onlyme-
tabolized by hexose-6-phosphate dehydrogenase, indicating that requisite NADPH for 21-hydroxylase activitywas
not via glucose-6-phosphate dehydrogenase. Moreover, dihydroepiandrostenedione, a non-competitive inhibitor
of glucose-6-phosphate dehydrogenase, but not hexose-6-phosphate dehydrogenase, did not curtail activation
by glucose-6-phosphate. Finally, themost compelling observationwas that themicrosomal glucose-6-phosphate
transport inhibitor, chlorogenic acid, blunted the activation by glucose-6-phosphate of both 21-hydroxylase and
17-hydroxylase indicating that luminal hexose-6-phosphate dehydrogenase can supply NADPH for these
enzymes. Analogous kinetic observations were found with microsomal 17-hydroxylase. These ﬁndings in-
dicate that hexose-6-phosphate dehydrogenase can be a source, but not exclusively so, of NADPH for seve-
ral adrenal P450 enzymes in the steroid pathway. Although the reduced pyridine nucleotides are produced
intra-luminally, these compounds may also slowly transverse the endoplasmic reticulum membrane by
unknown mechanisms.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
There are at least two cellular sub-compartmentalized enzymes
which, upon oxidation of glucose-6-phosphate (G6P), provide pyridine
reducing equivalents (NADPH and NADH) for other downstream reac-
tions: cytosolic glucose-6-phosphate dehydrogenase (G6PDH) and en-
doplasmic hexose-6-phosphate dehydrogenase (H6PDH). H6PDH has
been localized to the lumen of the endoplasmic reticulum (ER), spa-
tially and perhaps kinetically linked to 11β-hydroxysteroid dehy-
drogenase 1 (11β-HSD1) [1,2]. An elevated NADPH/NADP pyridine
nucleotide redox ratio must be maintained for reductase activationrogenase; G6PDH, glucose-6-
11β-HSD1, 11 beta hydroxy-
YP17, 17-hydroxylase; G6P,
-P, glucosamine-6-phosphate;
0, Birmingham, AL, 35233, USA.
rights reserved.of inert 11-oxosteroids. Although other NADPH-producing enzymes
have been foundwithin the ER, namely,malic enzymeand isocitrate de-
hydrogenase, neither appears to kinetically interact with 11β-HSD1 as
does H6PDH [3,4].
H6PDH is a bifunctional enzyme kinetically linked with 11β-HSD1
that is also functionally related to the cytosolic G6PDH. However,
unlike its cytosolic counterpart, H6DPH will metabolize a variety of
other hexose substrates [5]. H6PDH not only metabolizes G6P, but
also catalyzes the hydrolysis of 6-phosphogluconolactone, thereby
serving as the ﬁrst two enzymes of the oxidative segment of the pen-
tose pathway [6].
11β-HSD1 is a bidirectional enzyme which has both reductase and
dehydrogenase activities and is robustly expressed in liver, adrenal
and adipose tissue [2,7]. The directional ﬂux is determined by the
mass action ratio of pyridine nucleotides [8]. These compounds exist
in concentrations far exceeding the actual steroid reactants and dic-
tate the net-ﬂux interconversion of inactive ketosteroids (i.e., corti-
sone and dehydrocorticosterone) to their active hydroxy derivatives
(cortisol and corticosterone). Nonetheless, other enzymes within the ER
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zymes 17-hydroxylase (CYP17) and 21-hydroxylase (CYP21), functioning
asmonooxygenases to reducemolecular oxygen [9]. In the ER theNADPH
electrons are transferred by the tandem of P450 oxidoreductase and allo-
steric cytochromeb5. CYP17has been found inmicrosomes obtained from
adrenal glands, liver, gonads and placenta [9,10]whereas CYP21 has been
localized to microsomes in the adrenal cortex and kidney [11–13].
The nutrient G6P transverses the intact microsomal membrane by a
speciﬁc G6P transporter [14–16]. G6P is the physiologic substrate
for H6PDH as well as G6PDH, but there are several key kinetic distinc-
tions. Only H6PDH, being not as speciﬁc as G6PDH, will oxidize other
hexose phosphoesters such as glucosamine-6-phosphate (Gln-6-P)
and 2-deoxyglucose-6-phosphate [1]. In addition, DHEA is a well recog-
nized non-competitive inhibitor of hepatic G6PDH [17–21], but does
not alter H6PDH [22,23]. While nearly all previous studies have ex-
plored the role of H6PDH as it pertains to its kinetic interaction with
11β-HSD1 in adipose and liver tissue, our studies extend to the adrenal
glucocorticoid synthetic pathway.
Based on the experimental ﬁndings herein, H6PDH can provide
NADPH for both 21- and 17-hydroxylase, although it remains uncer-
tain to what extent insofar as other enzymatic avenues for NADPH
provision co-exist.
2. Materials and methods
2.1. Materials
[3H]-17-hydroxyprogesterone and [3H]-progesterone were pur-
chased from American Radiolabeled Chemicals (St. Louis, MO, USA).
Other compounds and general chemicals were from Sigma–Aldrich
(St. Louis, MO, USA). The G6PDH antibody (Rabbit anti human G6PDH)
was from Santa Cruz Biotechnology (Dallas, TX).
2.2. Preparation of adrenal microsomes
All animal procedures were undertaken with approval and over-
sight of the Institutional Animal Care and Use Committee (IACUC) at
the University of Alabama Birmingham.
Microsomeswere isolated from adrenals of Yorkshire pigs (30–40 kg
body weight). Care was taken to excise cortex by visible inspection. All
tissue samples were homogenized in an ice-bath with 4 vol. of 0.25 M
sucrose and 50 mM Tris/HCl, pH 7.3. The homogenate was centrifuged
for 10 min at 1000 g. The supernatant portion was removed and cen-
trifuged for 20 min at 10,000 g. Thereafter, the subsequent supernatant
was centrifuged for 60 min at 100,000 g. The resulting pellet was
washed twice with the same buffer. The microsomes were resuspended
at a protein concentration of 15–20 mg/ml (measured using the Bio-Rad
protein assay). To shed cytosolic enzymes such as G6PDH or other con-
taminants which may possibly adhere to microsomal membranes, the
microsomes were washed with polyethylene glycol (7% (w/v) ﬁnal con-
centration) as previously described [3,24] and resuspended inMOPS–KCl
buffer (100 mM KCl, 20 mM NaCl, 3.5 mM MgCl2 and 20 mM MOPS,
pH 7.2). Intactness of microsomes was conﬁrmed by using a method
with glucose dehydrogenase [25].
2.3. Puriﬁcation of glucose-6-phosphate dehydrogenase and effect of
G6PDH antibody
G6PDHwas puriﬁed according to the method previously described
by Clarke et al. [6]. Porcine adrenal gland cells were solubilized and
centrifuged to remove mitochondria. The cytosolic supernatant was
then applied to a 2′,5′-ADP-sepharose column. The G6PDHwas eluted
with a washing buffer that included 50 μM NADP.
In some experiments, G6PDH antibody (Santa Cruz Biotechnology,
Dallas, TX) was incubated at a protein concentration of 10 μg/ml for20 min at 37 °C in MOPS–KCl buffer (pH 7.2) with puriﬁed G6PDH
or adrenal microsomes before speciﬁc enzyme assays.2.4. Measurement of microsomal NADPH production
A sensitive micro-method was adopted to assay NADPH through
the conversion of radio-labeled α-ketoglutarate to glutamate [26].
Stoichiometrically, the oxidative deamination of 1 mol of glutamate
generates 1 mol of NADPH (or NADH) — the same stoichiometric
relationship holds true for the reverse reaction. Ten microliters of
microsomes (1 mg/ml) was pre-incubated for 15 min in MOPS–KCl
buffer (100 mM KCl, 20 mM NaCl, 3.5 mM MgCl2 and 20 mM MOPS,
pH 7.2). The reaction was initiated with 90 μl of 50 mM HEPES–
NaOH buffer (pH 7.4) reaction mixture (containing 50 mM ammo-
nium acetate,1 mM ADP, 0.5 μCi [14C]-α-ketoglutarate, 0.8 μM
α-ketoglutarate, 12 Units/ml glutamate dehydrogenase, 12 Units/ml
G6PDH). After incubating for 30 min at 37 °C, the reactionswere arrested
with cold water and 2 M HCl. To separate the unreacted [14C]-α-
ketoglutarate, samples were placed on anion exchange Dowex-50
columns. The reaction product was eluted with 3 mL of 2 M NH4OH;
the [14C]-glutamate was quantiﬁed by a scintillation counter.2.5. Measurement of G6DPH with various phosphoesters
G6PD activity was measured spectrophotometrically by monitoring
G6P dependent NADP reduction at 340 nm. The reaction was initiated
by adding 1 mM G6P into an enzyme solution containing 1 mM NADP
in Tris–HCl buffer, pH8. The reactionwas linear over 10 min at room tem-
perature. The protein concentration in the reaction was 50–60 μg/ml [6].
One international unit of G6PD activity is deﬁned as the reduction of
1 μmol NADP/min.2.6. Measurement of 21-hydroxylase and 17-hydroxylase activities
The microsomal 21-hydroxylase and 17-hydroxylase activities were
assayed by measuring conversion of 17-hydroxyprogesterone (17OH-P)
to 11-deoxycortisol and the loss of radiolabeled progesterone to products,
respectively. As for microsomal 21-hydroxylase, insofar as the terminal
step to cortisol occurs in the mitochondria, nearly all the converted
[3H]-17 hydroxyprogesterone appears in the 11-deoxycortisol band. As
for 17-hyroxylase, besides promoting 21-carbon cortisol ﬂux, it also gen-
erates 19-carbon androgen precursors through its intrinsic lyase activity.
Consequently, the absolute loss of radiolabeled progesterone, rather
than assaying all the products, best represents 17-hydroxylase activity.
Parenthetically, approximately 90–95% of the [3H]-progesterone sub-
strate was converted to the combined radioactivity found in 17OH-P
and 11-deoxycortisol. This is consistent with previous experiments
usingporcine adrenalmicrosomeswhereinCYP17 exhibits proportionally
modest lyase activity vs. robust 17-hydroxylation [27].
The reactionswere conducted at 37 °C for 15 min inMOPS–KCl buffer
(pH 7.2) containing 1 mM NADP+, 5 μM 17-hydroxyprogesterone and
0.2 μCi/ml [3H]-17-hydroxyprogesterone (21-hydroxylase assay), or
5 μM progesterone and 0.2 μCi/ml [3H]-progesterone (17-hydroxylase
assay). The reaction was started by the addition of microsomes (0.5 mg
protein/ml) and terminated by submerging the tubes in ice and simulta-
neously adding three volumes of ethyl acetate (21-hydroxylase assay) or
nine volumes of dichloromethane (17-hydroxylase assay). Steroids were
then extracted and separated on silicon-coated thin layer chromato-
graphy plates (Whatman Inc., Piscataway, NJ) using chloroform:ethanol
(95:5) as solvent system for 21-hydroxylase measurement or chloro-
form:ethyl acetate (4:1) for 17-hydroxylase measurement. Results are
expressed as pmol/mg protein/min. For the experiments in which DHEA
was added, it was dissolved in DMSO 0.1% (v/v).
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Fig. 2. Puriﬁed adrenal glucose-6-phosphate dehydrogenase activity: effect of various
substrates. Puriﬁed porcine adrenal glucose-6-phosphate dehydrogenase activity was
measured as per methods using the following substrates/modiﬁers: G6P (1 mM), G6P
(1 mM) + DHEA (100 μM), glucose (600 mM) or glucoseamine-6-phosphate (Gln-6-P)
(6.6 mM). All incubations included 1 mM NADP. Results are presented as a mean ± SD,
n = 4. All statistical comparisons (by unpaired t test) versus the G6P group were signiﬁ-
cant at p b .001.
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Data are presented as mean ± SD (n). The signiﬁcance of differ-
ences between groups was determined by Student's t-test and analysis
of variance. P b 0.05 was considered signiﬁcant. All statistical analyses
were performed with GraphPad Prism software (San Diego, CA, USA).
3. Results
3.1. Effect of G6P on NADPH production by intact adrenal microsomes
For 15 min, isolated intact adrenal microsomes were incubated
without and with G6P and/or NADP; thereafter, NADPH was measured.
In the absence of either metabolite (control), NADPH production was
negligible. With NADP, a trace amount of NADPH was detected. When
1 mM NADP and 1 mM G6P were combined, NADPH production rose
to 1.47 nmol/mg protein (Fig. 1). To a far lesser extent, high (600 mM)
glucose concentration likewise increased microsomal NADPH.
3.2. Puriﬁed adrenal glucose-6-phosphate dehydrogenase activity
Puriﬁed porcine adrenal glucose-6-phosphate dehydrogenase activ-
ity was measured with various substrates. Whereas activity was brisk
with 1 mM G6P (0.26 IU/mg protein) it was 90% inhibited by DHEA
(100 μM). Glucose, on the other hand, only marginally activated
G6PDH (6% compared to G6P) while Gln-6-P (6.6 mM) was in essence
inert (Fig. 2). These experiments employed 600 mM glucose based on
the high Km of H6DPH for glucose and near zero activation was antici-
pated below 10 mM [1,28].
3.3. Effect of various hexose phosphoester substrates on 21-hydroxylase
and 17-hydroxylase activity
NADPH is required for the conversion of [3H]-17-OH progesterone
to [3H]-11-deoxycortisol. Fig. 3 shows that F6P and G6P served as
excellent substrates, increasing [3H]-11-deoxycortisol production 10
and 12 fold, respectively. This ﬁnding corroborates earlier evidence by
our lab [29] and others [30] that both of these hexose-phosphoesters
can stimulate 11βHSD1. In the case of F6P, the stimulation is indirect,
that is, via conversion to G6P by microsomal isomerase [30]. Gln-6-P
(6.6 mM), in contrast, increased production by 2 fold, suggesting thatN
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Fig. 1. Effect of G6P and high glucose concentration on NADPH production by intact
adrenal microsomes. Isolated intact adrenal microsomes were incubated according to
the methods for 15 min as follows: no additions (control), 1 mM NADP, 1 mM G6P,
1 mM NADP + 1 mM G6P, 1 mM NADP + 600 mM glucose, 1 mM NADP + 1 mM
F6P, 1 mMNADP + 6.6 mMGlcN6P. Results are given as a mean ± SD, n = 3. Statistical
differences were by unpaired t test (NADP versus NADP + G6P or versus NADP +
glucose or NADP + F6P or NADP + GlcN6P were all p b .001). There was no statisti-
cal difference between the control, NADP or G6P alone groups.cytosolic or membrane adherent G6PDH is unlikely providing NAPDH
in adrenal ER (i.e. the puriﬁed enzyme had negligible activity with
Gln-6-P as a substrate per Fig. 2). The activities of 21-hydroxylase and
17-hydroxylasewere directly related to G6P concentration (Fig. 4). Glu-
cose at 600 mMstimulated both enzymes to a small degree at this high,
non-physiologic concentration (Fig. 5). To rule out a non-speciﬁc os-
motic effect, both sucrose and mannitol were also tested [25]. At
600 mM, both compounds were ineffective in modifying both 21- and
17-hydroxylases activities.3.4. DHEA inhibition of 21-hyroxylase activity
When DHEA – a known non-competitive G6PDH inhibitor – was
added at up to 1 mM, the identical concentration as G6P, there was no
inhibition detected (Fig. 6). Insofar as DHEA at 0.1 mM profoundly re-
duced partially puriﬁed G6PDH activity (see Fig. 2), the preservation
of G6P activation of 21-hydroxylase despite the presence of 1 mM
DHEA supports H6PDH as a provider of NADPH, not cytosolic G6PDH.
Moreover, polyclonal anti-G6PDH inhibited puriﬁed adrenal G6P activ-
ity by 70–85%, yet had no effect on the activation of 21-hydroxylase by
G6P when added to the intact microsomal experiments (data not
shown). If residual cytosolic G6PDH remained, despite washing
the microsomes, the addition of the anti-G6PDH should have atten-
uated, even to a limited degree, the G6P activation of 21-hydroxylase—
evidence again that G6PDH provided the obligate NADPH.0 5 10 15 20
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Fig. 3. Effect of hexose phosphate substrates on 21 hydroxylase activity. Isolated intact
adrenal microsomes were incubated with either 1 mM G6P, 1 mM F6P or 6.6 mM
glucoseamine-6-phosphate (GlcN6P) and 21-hyroxylase activity was measured over
20 min in the presence of 1 mM NADP. In each experiment, NADP was at 1 mM. Results
are expressed as a rate (pmol/mg) mean ± SD, n = 4.
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Fig. 4. 21-Hydroxylase and 17-hydroxylase activity in porcine adrenal microsomes.
Isolated intact adrenal microsomes were incubated for 15 min with increasing concen-
trations of G6P and 21-hydroxylase and 17-hydroxylase activities measured as per
methods with 1 mM NADP. Results are presented as mean ± SD, n = 4.
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Fig. 6. Effect of dihydroepiandrostenedione (DHEA) on 21-hydroxylase activity in adrenal
microsomes. Isolated intact adrenal microsomes were incubated for 15 min with 1 mM
G6P, 1 mM NADP and between 0 and 1 mM DHEA (an inhibitor of G6PDH) according to
methods. Results are given as a mean ± SD, n = 4. There were no statistically signiﬁcant
differences.
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21- and 17-hyroxylase activities
When chlorogenic acid at 1 mMwas added to the 15 minute reac-
tion, there was, respectively, a 70% and 75% reduction in the G6P
stimulation of 21-hydroxylase and 17- hydroxylase (Fig. 7). Because
of the ER luminal orientation of H6PDH, which is fully dependent
on the transport of the substrate G6P, this data again reinforces the
capability of H6PDH to supply NADPH for these two P450 cytochrome
enzymes. Considering the possibility that 1 mM chlorogenic acid
could directly inhibit these enzymes, they were assayed as previously
described except the nucleotide NADP was replaced by NADPH,
thereby eschewing the need for the G6P transporter-H6PDH tandem
to generate NADPH and the microsomes were rendered permeable.
Under these assay conditions using CHAPSO (a zwitter ionic, non-
denaturing detergent) permeabilized microsomes, with NADPH but
without G6P, chlorogenic acid (CA) did not alter the activity of either
CYP enzymes. Compared to basal rates (=100%, no added CA), the
effect of added CA on 21-hydroxylase activity was 96%, 99.9% and
97% of basal with 0.1 mM, 0.5 mM and 1 mM CA, respectively. In sum,
CA did not directly alter the activity of either CYP enzyme.
4. Discussion
The role of adrenal hexose 6-phosphate dehydrogenase in provid-
ing reducing equivalents to P450 cytochrome steroidogenic enzymes
in the endoplasmic reticulum (ER) is uncertain. Insofar as numerousG6P Glucose GlcN6P Sucrose Mannitol
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Fig. 5. Effect of various substrates and osmotic agents on 21-hydroxylase and 17-
hydroxylase activity in porcine adrenal microsomes. Isolated intact adrenal microsomes
were incubated for 15 min with G6P (1 mM), glucose (600 mM), GlucN6P (6.6 mM),
sucrose (600 mM) and mannitol (600 mM) and the activities of 21-hydroxylase and
17-hydroxylase measured as per methods with 1 mM NADP. Results are given as
mean ± SD, n = 4.ER enzymes require an electron donor (NADPH), it is conceivable
that H6DPH serves in that capacity for several steroid pathways.
H6PDH resides in the ER lumen and co-localizes with the bidirec-
tional enzyme 11β-HSD1. Given this spatial protein-to-protein interac-
tion with 11β-HSD1, it is likely that H6PDH provides 11β-HSD1 with
NADPH electrons via substrate channeling. The enzymatic source(s)
providing reducing equivalents for microsomal steroid-synthesizing
P450 enzymes is ill-deﬁned. Hexose-6-phosphate dehydrogenase
has been found throughout adrenal tissue [22]. Previous studies
have convincingly demonstrated that H6PDH is likely the major
source of reduced pyridine nucleotides for 11β-HSD1 within the ER
lumen of liver and fat [4,7,31,32]. However, few studies have ex-
plored its role in adrenal tissue, particularly as pertains to disparate
P450 steroidogenic enzymes.
In adrenocortical cells, reduced pyridine nucleotides generated from
enzymatic conversion of G6P can be provided by either microsomal
H6PDH or cytosolic G6PDH. In our enzyme studies, any residual
G6PDH not initially eliminated in the preparation of the washed micro-
somes, yet possibly adherent to the outer ER membrane, was expunged
by polyethylene glycol washes. The activity of adrenal 21-hydroxylase
and17-hydroxylasewas assayed usingG6P, Gln-6-P, andglucose as sub-
strates. There was signiﬁcant increase in enzymatic activity with each.
H6PDH can metabolize glucose, but only at very high non-physiologicControl CA CA Control
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Fig. 7. Effect of chlorogenic acid (CA), an inhibitor of microsomal G6P transport, on G6P-
stimulated 21- and 17-hyroxylase activities. Isolated intact adrenal microsomes were
incubated for 15 min. The control group included 1 mM G6P and 1 mM NADP. The CA
group contained 1 mM chlorogenic acid (CA) with 1 mM G6P and 1 mM NADP. Both
21-hydroxylase and 17-hydroxylase activities were measured as per methods. Results
are expressed relative to the control for each enzyme and as a mean ± SD.
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lated both 21- and 17-hydroxylases. This was not due to a non-speciﬁc
osmotic effect because neither 600 mMmannitol nor sucrose modiﬁed
enzyme activity.
In microsomes prepared from H6DPH knockout mice, only 11β-
HSD1 dehydrogenase activity – as opposed to reductase –was detected
with consequent impaired active steroid recovery [34]. If G6PDH was
the primary source of NADPH for reductase activity for 11β-HSD1 in
peripheral tissues, or for steroid synthesis in adrenal tissue, there
would be no activation of the hypothalamic–pituitary–adrenal (HPA)
axis. Yet H6PDH deﬁcient mice have glucocorticoid deﬁciency with a
corresponding increase in the HPA axis, as evidence by increased circu-
lating ACTH [35,36]. H6PDHmay serve a pivotal role in not only supply-
ing NADPH for co-localized luminal 11β-HSD1, but also, under certain
conditions, for the provision of electrons to other key P450 enzymes
within adrenal microsomes.
To further corroborate that the NADPH was generated by H6DPH
rather than G6DPH, the speciﬁc enzymatic inhibition by DHEA of
the latter was explored [22,23]. DHEA is a well recognized inhibitor
of G6PDH [18,20,21]; for example, at only 0.05 mM, DHEA inhibits
hepatic G6PDH in vitro Vmax activity by nearly 75%[22,23]. Results
from our study conﬁrm inhibition of puriﬁed porcine adrenal G6PDH
with DHEA (an 89% inhibition at 1 mM DHEA). Moreover, using
10 mM G6P as substrate, a previous study showed 95% inhibition of
G6PDH by DHEA using adrenal cortex tissue [37]. These inhibition
results are in stark contrast to our ﬁndings in intact microsomes: no
attenuation of the G6P activation of CYP21 and CYP17 by a high con-
centration of DHEA. Also, using intact microsomes, the addition of
anti-G6PDH antibody to the assay did not alter the G6P stimulation of
21-hydroxylase.
Finally, the possible role of H6PDH in the provision of NADPH for
two ER enzymes is supported by the effect of G6P transport inhibi-
tion. If indeed cytosolic G6PDH is, as previously opined, the sole pro-
vider of reduced pyridine nucleotides, then chlorogenic acid should
have had a nugatory effect on the activation by G6P of the P450
enzymes — this was certainly not the case. The observation that the
G6P transport inhibitor, chlorogenic acid (CA), signiﬁcantly blunted
the activation of both CYP21 and CYP17 by G6P corroborates that
H6PDH can be an auxiliary enzyme for NADPH production. And, of
note, CA did not directly inhibit either enzyme when NADPH replaced
NADP in the absence of G6P in permeabilized microsomes.
As is the case with most cytochrome P450 enzymes, the topo-
graphical orientation of 21-hydroxylase has a cytosolic orientation
[38,39]. This topology is antithetical to that of 11β-HSD1 wherein its
N-terminal transmembrane domain begets a luminal orientation of
the catalytic moiety [40,41]. This enzyme depends on H6PDH as its
NADPH source to promote reductase over dehydrogenase activity.
Therefore, at present, it is hard to reconcile the ER luminal locus of
H6PDH, the ensuing luminal production of NADPH following the ingress
of G6P, and the eventual activation of a cytosolic oriented cytochrome
P450 enzyme. Nevertheless, it is not unprecedented that some ER
enzymes may have a dual membrane orientation, as in the case with
diacyglycerol acyltransferase I and some oligomeric enzymes [42].
Furthermore, for 21-hydroxylase, based on rotational diffusion
studies and other methods, using protease digestion, the anchoring
of the enzyme to the ER membrane appears to be unusually deeply
embedded [43,44]. Does this atypical membrane attachment dispose
or facilitate luminal pyridine nucleotide contact with CYP21? Or,
perhaps, do pyridine nucleotides cross the ER membrane, albeit in a
limited fashion? Over brief periods (b10–15 min) of incubation,
these nucleotides appear to be impermeant to the microsomal mem-
brane, whereas with more prolonged incubations, and with mem-
branes proven to be still intact, there is clearly a slow penetrance of
NADPH [45–49]. Many experimental observations from unrelated
studies can be adduced wherein pyridine nucleotides unmistakably
gain access to themicrosomal lumen, even in the absence of detergentsor permeabilizing agents. These studies involve primarily microsomes
from rat liver, but similar data is found in HEK-293 cell microsomes
[32]. Based on measurements of accumulated radioactivity following
incubation of liver microsomes and radio labeled G6P, it was concluded
that NADPH can slowly penetrate themembranes [45]. In humanswith
severe G6PDH deﬁciency, and despite a basal mean adrenal enzyme
activity 13% of normal [50], there is no evidence of impaired cortisol
synthesis or clearance. Compared to 43 controls, 10 subjects with
G6PDH enzyme deﬁciency had normal basal and ACTH-stimulated
serumconcentrations. This data suggests, at least in humans, alternative
sources of the requisite NADPH for steroid synthesis, either via the oxi-
dative decarboxylation of malate, isocitrate dehydrogenase or endo-
plasmic H6PDH. Another possibility which has been proposed is that
there is an ER membrane electron shuttle, yet to be discovered, much
like what occurs in mitochondria. Of comparable weight, a transporter
for ATP exists in the ER [51].
5. Conclusions
In conclusion, in intactmicrosomes,H6DPH can provide the reducing
electrons for at least two adrenal P450 enzymes involved in glucocorti-
coid synthesis. Several ﬁndings buttress this premise. Firstly, unique
phosphoesters and high concentrations of glucose, which are not (or
minimally) utilized by cytosolic G6PDH, increase the enzyme activity
of 21-hydroxylase and 17-hydroxylase. Secondly, upon addition of G6P
to intact microsomes, no curtailment of G6P-stimulation of CYP21 and
CYP17 was noted with a G6PDH inhibitor, DHEA. Thirdly, upon blocking
the ingress of G6P in intact microsomes, the stimulation of both CYP21
and CYP17 was substantially curbed. In sum, H6PDH, besides its kinetic
interactionwith 11β-HSD1, may play a role in electron transfer for mul-
tiple P450 steroidogenic enzymes.
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